Actelion is a Switzerland based biopharmaceutical company discovering, developing and commercializing products for unmet medical needs. The company is now part of the world’s top 50 biotech companies and is present with its subsidiaries in over 30 countries worldwide.
The primary therapeutic focus for Actelion is cardiovascular, specifically Pulmonary Arterial Hypertension (PAH), it offers 4 key products in this indication and has 3 evolving medications thriving in its busy developmental product pipeline.
The company’s other therapeutic areas of interest are;
- Digital ulcers
- Type 1 Gaucher Disease
- Niemann Pick Type C
- Mycosis Fungoides
Actelion was formed in 1997 by cardiologist Jean-Paul Clozel, the company was one of the first companies to carry out specialist research on endothelial receptor antagonists. From those early days Actelion has grown to be a huge biotech company challenging cardiovascular science and building its operations through internal growth, in-licensing partnerships and acquisitions of strategic targets.
Quality not quantity
When it comes to partnering Actelion has decided to take an approach where it selects quality over quantity; the company has partnered with only a select few companies in its short history through in-licensing and acquisitions arrangements, including Auxilium Pharmaceuticals and Bayer AG. The company has said to select only ‘sophisticated’ partnerships in order to access the technologies or products it has its eyes on. The aim ultimately of these partnerships is to expand its range of marketed products, build infrastructure and know-how, complement its existing innovations and maximize the strength of its internal projects.
Once a partnership has been initiated with Actelion, it describes its partnering approach to be rapid, pro-active and open, hopefully aiming to create benefits for both parties. The company has a specialist team in place that is committed solely to finding partnerships that match its business approach.
Actelion’s few acquisitions have been very strategic too in terms of the company’s long term commitment to cardiovascular and oncology treatments; in 2003 Actelion acquired the company Axovan which along came with it the endothelin receptor agonist Clazosentan, four years later in 2007 CoTherix was the next acquisition target who owned the successful product Ventavis and finally fairly recently in 2013 Ceptarlis were acquired by Actelion, which also meant that it became the new owners of Ceptarlis’ oncology gel Valchlor. These sporadic acquisitions have strengthened Actelion product portfolio in these key therapeutic markets.
Actelion is often present at a large number of partnering events throughout the year. Partnering events are a great place to meet lots of potential partners face to face in a short space of time.
Events with Actelion presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Actelion in person visit Current Partnering’s Event calendar.
Contacting Actelion for partnering
Actelion can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with Actelion’ business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. This page on the Actelion website has details for contacting Actelion.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.
Many of Actelion’s business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit the Actelion Linkedin Page
Actelion partnering at Current Agreements
Full details on each deal can be found at CurrentAgreements (subscription required)
Or purchase report: Partnering Agreements with Actelion 2009-2014
Available reports from Current Partnering
Report: Partnering Agreements with Actelion 2009-2014
Report: Partnering Deals and Alliances with Big Biotech
Available resources for deal coverage for Actelion
Read: more on Actelion company profile, recent partnering, M&A and financing news and articles
Report: Practical Guide to Finding Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk